Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SY-1425, a potent and selective RARĪ± agonist, in combination with azacitidine demonstrates a high complete response rate and a rapid onset of response in RARA-positive newly diagnosed unfit acute myeloid leukemia
    Meeting Abstract

    De Botton, S.; Cluzeau, T.; Vigil, C. E.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Longitudinal molecular profiling in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib
    Meeting Abstract

    Choe, S.; Wang, H.; Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; Mims, A. S.; Prince, G. T.; Watts, J. M.; Fan, B.; Nejad, P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Trial in progress: A phase I trial of BTX-A51 in patients with relapsed or refractory AML or high-risk MDS
    Meeting Abstract

    Ball, B. J.; Stein, A. S.; Borthakur, G.; Murray, C.; Kook, K.; Chan, K. W.; Stein, E. M.
    Blood (2020)

    Fulltext@MSK | Save
  • Trials in progress: A phase I study to evaluate the safety and pharmacokinetic profiles of CB-5339 in participants with relapsed/refractory acute myeloid leukemia or relapsed/refractory intermediate or high-risk myelodysplastic syndrome
    Meeting Abstract

    Benajiba, L.; Carraway, H. E.; Hamad, N.; Stein, E. M.; Yannakou, C. K.; Burroughs, A.; Harris, S.; Lane, H.; Nguyen, D. D.; Stuart, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: Feasibility and preliminary efficacy of the Beat AML Master Trial
    Research Letter

    Burd, A.; Levine, R. L.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P.; Baer, M. R.; Stock, W.; Deininger, M.; more...
    Nature Medicine (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
    Meeting Abstract

    Dinardo, C. D.; Stein, E.; Pigneux, A.; Altman, J. K.; Collins, R.; Erba, H. P.; Watts, J. M.; Uy, G. L.; Kapsalis, S. M.; Liu, H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)
    Meeting Abstract

    Dinardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition
    Journal Article

    Cai, S. F.; Chu, S. H.; Goldberg, A. D.; Parvin, S.; Koche, R. P.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agent
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save